Dr. Daniel N. Egan, MD
Hematology & Oncology (Hematology & Oncology Physician)
1221 Madison St Ste 1020
Seattle, WA 98104
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Massachusetts Medical School (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 150
Licensed in Washington since 2011, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Massachusetts Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD60212119 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Swedish Medical Center Seattle, WA
Medical groups
- Swedish Health Services (1,037 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 150
- Services billed
- 446
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 280 | 95 |
| Established patient office or other outpatient visit, 40-54 minutes | 100 | 47 |
| Established patient office or other outpatient visit, 20-29 minutes | 21 | 19 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | 16 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Seattle, WA | 163 |
| Hydroxyurea Other prescribers in Seattle, WA | 59 |
| Jakafi (ruxolitinib phosphate) | 57 |
| Eliquis (apixaban) Other prescribers in Seattle, WA | 54 |
| Revlimid (lenalidomide) | 52 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Seattle, WA | 38 |
| Gabapentin Other prescribers in Seattle, WA | 35 |
| Venclexta (venetoclax) | 35 |
| Onureg (azacitidine) | 32 |
| Posaconazole | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $146 in total to this clinician.
| Ferring Pharmaceuticals Inc. | $105 |
|---|---|
| Genzyme Corporation | $16.20 |
| Adc Therapeutics America, Inc. | $16.00 |
| Pfizer Inc. | $8.54 |
| Food and Beverage | $146 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 5 companies. The companies reported $273,373 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05283720 - A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Celgene Corporation - A phase 1, multicenter, open-label study of cc 95266, g protein-coupled receptor class c group 5 member d (GPRC5D)-targeted chimeric antigen receptor (car) t cells, in subjects with relapsed and/or refractory multiple…
Celgene Corporation - A phase 1B2 openlabel study of PF07901801 in combination with glofitamab after a fixed single dose of obinutuzumab in participants with relapsedrefractory diffuse large b cell lymphoma not eligible for stem cell trans…
Pfizer Inc. - M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
AbbVie Inc. - An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Celgene Corporation · Completed · NCT03601078 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie Inc. · Active, not recruiting · NCT03844048 - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie Inc. - A phase 1 study of SEACD70 in myeloid malignancies
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.